Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology” start-ups.

Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s websi Regeneron Pharmaceuticals, Inc. and Society ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Analysts at Leerink Partners said Monday that the probe was “expected.” After all, President Donald Trump over the past few weeks has signaled his intent to impose tariffs on the pharma industry. “The ...

At close: April 11 at 4:00:01 PM EDT ...

This week, much of the world got a re­prieve from Pres­i­dent Don­ald Trump’s tar­iffs. Drug­mak­ers might not be so for­tu­nate.